Revolution Medicines, Inc. (NASDAQ: RVMD) is a biotechnology company focused on developing targeted therapies for cancer. The company is known for its innovative approach to oncology, which has attracted interest from major pharmaceutical companies. Revolution Medicines competes with other biotech firms in the oncology space, such as AbbVie Inc. and Merck & Co., Inc.
On January 27, 2026, Oppenheimer maintained its "Outperform" rating for RVMD, with the stock priced at $97.78. Oppenheimer also raised its price target for RVMD from $75 to $150, as highlighted by TheFly. This suggests confidence in the company's future performance despite recent challenges.
RVMD's stock price recently dropped by nearly 17% after Merck withdrew from acquisition talks. The potential deal was valued between $28 billion and $32 billion, with Revolution Medicines valued at approximately $30 billion. The Wall Street Journal reported that the negotiations stalled due to disagreements over the buyout price.
Despite the setback with Merck, there is still potential for future discussions. Merck's CEO, Robert Davis, mentioned the company's interest in high-growth oncology assets, although they typically target acquisitions valued at $15 billion or less. This disciplined approach may have contributed to the stalled negotiations.
Additionally, AbbVie was reportedly in advanced talks to acquire Revolution Medicines earlier in January. This indicates that other potential suitors may emerge, keeping the possibility of an acquisition alive. Revolution Medicines' market capitalization currently stands at approximately $18.9 billion, with a trading volume of 10,173,600 shares.
